IP Verse

Pharmaceutical Compositions Of Pemetrexed - EP2854768

The patent EP2854768 was granted to Fresenius Kabi Oncology on Jun 18, 2025. The application was originally filed on May 30, 2013 under application number EP13730070A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2854768

FRESENIUS KABI ONCOLOGY
Application Number
EP13730070A
Filing Date
May 30, 2013
Status
Patent Maintained As Amended
May 16, 2025
Grant Date
Jun 18, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

COOKEDec 22, 2017ELKINGTON AND FIFEADMISSIBLE
GENERICS UKDec 22, 2017FRKELLYADMISSIBLE
LARSEN & BIRKEHOLMNov 3, 2017LARSEN & BIRKEHOLMADMISSIBLE

Patent Citations (23) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONCN101081301
DESCRIPTIONUS2008139810
DESCRIPTIONUS2011201631
DESCRIPTIONUS5344932
DESCRIPTIONUS6686365
DESCRIPTIONWO2012001581
EXAMINATIONWO2010030598
INTERNATIONAL-SEARCH-REPORTCN100364993C
INTERNATIONAL-SEARCH-REPORTCN101081301
INTERNATIONAL-SEARCH-REPORTWO2012015810
OPPOSITIONCN100364993C
OPPOSITIONCN101081301
OPPOSITIONEP0432677
OPPOSITIONEP1313508
OPPOSITIONIS50051
OPPOSITIONUS2007190138
OPPOSITIONUS4977181
OPPOSITIONUS5344932
OPPOSITIONWO2008021411
OPPOSITIONWO2010030598
OPPOSITIONWO2012015810
OPPOSITIONWO2014167585
OTHERWO2010030598

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "alcohol", ROWE, R. C. et al., Handbook of Pharmaceutical Excipients, (20090000), pages 17 - 19 , 241-242, 517-522, XP055447695-
OPPOSITION- ANGUS Life Sciences, "TRIS AMINO® Tris Buffer", (20160300), XP055451806-
OPPOSITION- "a survey in the 1995 issue of index nominum yielded the following re-sults", STAHL et al., Handbook of Pharmaceutical Salts, Properties, Selection, and Use, (20110000), page 402-403,389,393-397, XP055447611-
OPPOSITION- Calvert, "An overview of Folate Metabolism: Features Relevant to the Action and Toxicities of Antifolate Anticancer Agents", seminars in oncology suppl, (19990400), vol. 26, no. 2, pages 3 - 10, XP008005750-
OPPOSITION- "chapter 2 solubility and dissolution of weak acids bases and salts", STAHL et al., Handbook of Pharmaceutical Salts, Properties, Selection, and Use, (20020000), pages 19-27,35,83-84,105-106, - 135-148,158-160,317-325,330, XP055447592-
OPPOSITION- "chapter 67 Tromethamine", limmer, The Science and Practice of Pharmacy, (20000000), page 1266, XP055447637-
OPPOSITION- Euroepan Medicines Agency, "Summary of Product Characteristics for Alimta®", (20090920), XP055451812-
OPPOSITION- European Medicinal Agency, "Summary of Product Characteristics for Pemetrexed Fresenius Kabi", (20160000), pages 1 - 67, XP055451815-
OPPOSITION- European Medicines Agency, "Pemetrexed Fresenius Kabi", Assessment Report EMA/CHMP/407425/2016, (20160526), pages 1 - 20, XP055451823-
OPPOSITION- HOVGAARD, L. et al., "Pharmaceutical Formulation Development of Peptides and Proteins", Pharmaceutical Formulation Development of Peptides and Proteins, (20120000), pages 158 - 161, XP055447630-
OPPOSITION- MROSZCZAK et al., "Keterolac Tromethamine Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics", Animals and Humans, Drug Metabolism and Disposition, (19870000), vol. 15, no. 3, XP055447620-
OPPOSITION- MROSZCZAK et al., "Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans", Drug Metabolism and Disposition, (19870000), vol. 15, pages 618 - 626, XP055447620-
OPPOSITION- MROSZCZAK et al., "Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans", Drug Metabolism and Disposition, (19870901), vol. 15, no. 5, pages 618 - 626, XP055451794-
OPPOSITION- "Pemetrexed", Drug Bank, (20160913), pages 1 - 11, XP055447641-
OPPOSITION- Phoenix Scienific, Inc., "Original New Animal Drug Aplication ANADA 200-253 ProstaMateâ„¢ (dinoprost tromethamine injection) Sterile Solution", Freedom of Information Summary, (19990212), pages 1 - 3, XP055451829-
OPPOSITION- Scientific Discussion for Alimta®-
OPPOSITION- "TRIS AMINO", ANGUS Life Sciences, (20160000), pages 1 - 9, XP055447623-
OPPOSITION- "tromethamine", STAHL, P. H. et al., Handbook of Pharmaceutical Salts Properties, Selection, and Use, (20080000), pages 324 - 325-
OPPOSITION- Tromethamine Wikipedia extract-
OPPOSITION- ZAMBON, CH, "Monurol® (fosfomycin tromethamine) SACHET", (20070000), pages 1 - 14, XP055451798-
OPPOSITION- BERGE et al., "Pharmaceutical salts", Journal of Pharmaceutical Sciences,, (19770100), vol. 66, no. 1, pages 1 - 19, XP002675560

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents